docetaxel anhydrous and Lung Adenocarcinoma
docetaxel anhydrous has been researched along with Lung Adenocarcinoma in 56 studies
Research
Studies (56)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 44 (78.57) | 24.3611 |
2020's | 12 (21.43) | 2.80 |
Authors
Authors | Studies |
---|---|
Fukushima, K; Hashida, N; Hirata, H; Iwahori, K; Koyama, S; Kuge, T; Kumanogoh, A; Matsumoto, K; Miyake, K; Nagatomo, I; Naito, Y; Shiroyama, T; Suga, Y; Takeda, Y; Yamamoto, M; Yamamoto, Y; Yoneda, M | 1 |
Chang, L; Chen, F; Chen, J; Fang, S; Gu, W; Li, C; Liu, W; Ma, J; Qian, Y; Yang, Z; Yuan, Y; Zhang, K | 1 |
Hashimoto, M; Hojo, M; Iikura, M; Ishida, A; Ishii, S; Izumi, S; Naka, G; Sugiyama, H; Ushio, A | 1 |
Igai, H; Kamiyoshihara, M; Matsuura, N; Numajiri, K; Ohsawa, F | 1 |
Bourlon, MT; Gabutti, A; Remolina-Bonilla, YA; Saldivar-Oviedo, B; Trejo-Rosales, RR | 1 |
Hoffman, RM; Hu, L; Liu, JB; Sun, YU; Yang, Z; Yi, Z | 1 |
Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
Acevedo-Delgado, JA; Acosta-Espinoza, A; Alatorre-Alexander, JA; Astorga-Ramos, AM; Barriguete-Parra, L; Campos-Gomez, S; Capdeville-García, D; Cázarez-Price, JC; Ceja-García, JP; Fernández-Garibay, VM; Flores-Anaya, N; Flores-Mariñelarena, RR; García-Montes, V; Gerson-Cwilich, R; González-Espinoza, IR; Gonzalez-Villanueva, JI; Kuri-Exsome, R; Magallanes-Maciel, M; Martínez-Barrera, L; Noriega-Iriondo, MF; Perales-Rodríguez, E; Perez-Lozano, Y; Rodríguez-Cid, JR; Rodríguez-Silva, C; Suárez-García, D; Vázquez-Cortés, L; Villalobos-Prieto, A; Zuloaga-Fernandez, CJ | 1 |
Furuya, N; Hataji, O; Hida, N; Inoue, T; Ito, K; Komase, Y; Mineshita, M; Morikawa, K; Sakaguchi, T | 1 |
Ando, M; Gemma, A; Hagiwara, K; Hino, M; Kobayashi, K; Kubota, K; Miyanaga, A; Nishitsuji, M; Noro, R; Seike, M; Shimokawa, T; Usuki, J; Yomota, M | 1 |
Atz, J; Azeh, I; Buchner, H; C Christoph, D; Hoffmann, C; Hoiczyk, M; Kambartel, K; Metzenmacher, M; Panse, J; Rizzo, F; Schaufler, D; Scheffler, M; Turki, AT | 1 |
Bai, H; Han, Y; Niu, Y; Zhang, M | 1 |
Chen, J; Chen, L; Chu, X; Pan, Y; Tao, L; Wang, R; Zhang, K | 1 |
Bennouna, J; Bondarenko, I; Douillard, JY; Gottfried, M; Heigener, DF; Kaiser, R; Krzakowski, M; Mellemgaard, A; Novello, S; Orlov, S; Reck, M; Stöhr, J; Summers, Y; von Pawel, J | 1 |
Alcaraz, J; Gabasa, M; Hilberg, F; Ikemori, R; Reguart, N | 1 |
Onari, Y; Otani, T; Yamane, M | 1 |
Gao, G; Ren, S; Wu, F; Zhang, S; Zhao, J; Zhou, C | 1 |
Fukasawa, Y; Haruyama, T; Honda, T; Ichikawa, Y; Ishihara, M; Natsume, M; Ota, S; Sakamoto, T; Sasajima, Y; Seki, N; Tanzawa, S; Usui, R; Watanabe, K | 1 |
Bell, AP; Jain, N; Jarvis, SP; Kilpatrick, JI; Liu, B; Movia, D; Prina-Mello, A; Tutty, MA; Volkov, Y | 1 |
Fusumae, T; Kawakita, R; Oda, S; Takasugi, A; Takeuchi, A; Yoshida, T | 1 |
Goto, K; Horinouchi, H; Kato, T; Kenmotsu, H; Morsli, N; Nakagawa, K; Saito, I; Sarashina, A; Takeda, K; Takeda, M; Tanaka, T; Yamamoto, N | 1 |
Cao, J; Chen, L; Chu, X; Geng, J; Huang, G; Wang, R | 1 |
Geng, Y; He, Z; Li, M; Li, Q; Liu, L; Lu, B; Luo, D; Ma, Z; OuYang, W; Su, S; Wang, Y; Yang, W; Zhao, C | 1 |
Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
Gandara, DR; Knollmann, FD; Lim, S; Narayanan, A; Riess, JW; Walby, JAS | 1 |
Bai, H; Duan, JC; Hao, XZ; Hu, XS; Li, JL; Lin, L; Liu, YT; Wan, R; Wang, HY; Wang, J; Wang, X; Wang, Y; Wang, ZJ | 1 |
Carcereny, E; Corral, J; Cortes, ÁA; Domine, M; García, Y; Llorente, M; López Criado, MP; López Picazo, JM; Majem, M; Rodríguez-Abreu, D | 1 |
Cao, F; Chen, D; Chen, L; Feng, J; Wang, R; Yan, F; Yu, C; Yu, Z; Zhang, X; Zhu, H | 1 |
Asai, Y; Gon, Y; Nakagawa, Y; Shimizu, T; Takahashi, N; Tsujino, I | 1 |
Hongo, H; Kosaka, T; Oya, M | 1 |
de Castro, J; Felip, E; García-Campelo, R; Garrido, P; Isla, D; Lianes, P; Paz-Ares, L; Trigo, JM | 1 |
Chen, LB; Chen, YT; Cui, SY; De, W; Feng, B; Huang, GC; Huang, JY; Song, HZ; Wang, R | 1 |
Chen, LB; Pan, BZ; Song, HZ; Wang, R; Zhang, YW; Zheng, Y | 1 |
Barrueco, J; Bondarenko, I; Douillard, JY; Gann, CN; Gaschler-Markefski, B; Gottfried, M; Kaiser, R; Krzakowski, M; Liao, M; Mellemgaard, A; Novello, S; Orlov, S; Reck, M; von Pawel, J | 1 |
Leighl, NB; Zer, A | 1 |
Chen, D; Chen, L; Feng, B; Huang, J; Pan, B; Song, H; Wang, R | 1 |
Chen, DQ; Chen, J; Chen, LB; De, W; Feng, B; Huang, JY; Pan, BZ; Wang, R; Zhang, K | 1 |
Chen, D; Chen, J; Chen, L; De, W; Huang, J; Pan, B; Wang, R; Zhang, K | 1 |
Dhillon, S | 1 |
Bartolotti, M; Brandes, AA; Cavallo, G; Dalpiaz, G; De Biase, D; Denicolò, F; Di Battista, M; Genestreti, G; Lazzari-Agli, LA; Trisolini, R; Valli, M | 1 |
Catino, A; De Ceglie, A; Galetta, D; Logroscino, A; Misino, A; Natalicchio, MI; Simone, G | 1 |
Cui, YQ; Geng, Q; Li, J; Lin, HC; Liu, L; Yan, MX; Yao, M; Yu, T; Zhang, FL; Zhu, MX | 1 |
Chen, L; Chen, Y; Feng, B; Huang, G; Pan, B; Song, H; Wang, R | 1 |
Aggarwal, C; Bauml, J; Brady, AK; Cohen, RB; Evans, TL; Judy, B; Langer, C; McNeill, JD; Vachani, A | 1 |
Bosenberg, MW; Held, MA; Iyidogan, P; Langdon, CG; Levy, F; Mamillapalli, R; Platt, JT; Stern, DF; Theodosakis, N; Vuagniaux, G; Wang, S; Wiedemann, N | 1 |
Chen, L; Chen, Y; Feng, B; Gao, Y; Song, H; Wang, R | 1 |
Wang, K; Zhang, K; Zhou, F; Zhu, L; Zhu, X | 1 |
Chen, J; Chen, LB; Chu, X; Pan, Y; Tao, L; Wang, R; Xu, Y; Zhang, K | 1 |
Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
Wang, L; Xiao, F; Zhang, W; Zheng, J | 1 |
Chen, Y; Hotta, K; Ichihara, E; Kiura, K; Ochi, N; Tabata, M; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D | 1 |
Chen, LB; Feng, B; Song, HZ; Wang, R | 1 |
Liu, G; Wang, W; Zhang, X; Zhu, X | 1 |
Jiao, S; Sun, S; Wu, L; Wu, Z; Yan, X; Zhao, X | 1 |
Reviews
4 review(s) available for docetaxel anhydrous and Lung Adenocarcinoma
Article | Year |
---|---|
Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Neoplasm Staging; Pyridines; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
A commentary on interstitial pneumonitis induced by docetaxel: clinical cases and systematic review of the literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents; Blood Gas Analysis; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Prednisone; Recovery of Function; Spirometry; Taxoids; Tomography, X-Ray Computed | 2015 |
Trials
7 trial(s) available for docetaxel anhydrous and Lung Adenocarcinoma
Article | Year |
---|---|
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Pleural Effusion, Malignant; Pleurodesis; Prognosis; Survival Rate | 2020 |
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Europe; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2017 |
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Feasibility Studies; Female; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; No-Observed-Adverse-Effect Level; Treatment Outcome | 2018 |
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2019 |
A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2019 |
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2014 |
Other Studies
45 other study(ies) available for docetaxel anhydrous and Lung Adenocarcinoma
Article | Year |
---|---|
Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunologic Factors; Immunotherapy; Lung Neoplasms; Ramucirumab; Treatment Outcome | 2022 |
Exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; RNA, Long Noncoding; RNA, Small Interfering; Transfection | 2022 |
A rare case of docetaxel-induced myositis in a patient with a lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Fatigue; Humans; Lung Neoplasms; Male; Myositis; Pain | 2022 |
[Multidisciplinary Treatment for Postoperative Recurrent Patients-Report of a Long-Term Survivor].
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Nivolumab; Pemetrexed; Survivors | 2022 |
What Are Treatment Options After Progression in PDL-1-Positive Metastatic Lung Adenocarcinoma after Chemo/IO?
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bone Neoplasms; Brain Neoplasms; Carboplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Pemetrexed; Prognosis | 2019 |
Aurora-A/NF-ĸB Signaling Is Associated With Radio-resistance in Human Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Cell Proliferation; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Radiation Tolerance; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Indoles; Lung; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Taxoids; Treatment Outcome | 2020 |
The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Safety; Prognosis; Ramucirumab; Retrospective Studies; Survival Rate | 2020 |
Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Treatment Failure | 2021 |
[Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
Topics: Adenocarcinoma of Lung; Adult; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Crizotinib; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Male; Mutation; Oncogene Proteins, Fusion; Pemetrexed; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2021 |
Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Microfilament Proteins; MicroRNAs; Phenotype; RNA Interference; RNA, Long Noncoding; Taxoids | 2017 |
Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Docetaxel; Fibroblasts; Fibrosis; Humans; Indoles; Lung Neoplasms; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Transforming Growth Factor beta1 | 2017 |
[A Case of Lung Cancer Associated with Drug-Induced Immune Thrombocytopenia].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Lung Neoplasms; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Taxoids | 2017 |
Paraneoplastic IgA Vasculitis in an Adult with Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Diagnosis, Differential; Docetaxel; Exanthema; Humans; Immunoglobulin A; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Purpura; Taxoids; Treatment Outcome; Vasculitis | 2018 |
Culturing substrates influence the morphological, mechanical and biochemical features of lung adenocarcinoma cells cultured in 2D or 3D.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Biophysical Phenomena; Cell Culture Techniques; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Lung Neoplasms; Microscopy, Confocal; Substrate Specificity; Taxoids; Tumor Cells, Cultured | 2018 |
Successful treatment of extramammary Paget's disease with S-1 and docetaxel combination chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Humans; Lung Neoplasms; Male; Oxonic Acid; Paget Disease, Extramammary; Pneumonectomy; Positron-Emission Tomography; Skin Neoplasms; Tegafur; Treatment Outcome | 2018 |
miRNA‑885‑3p inhibits docetaxel chemoresistance in lung adenocarcinoma by downregulating Aurora A.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; MicroRNAs; NF-kappa B; Proto-Oncogene Proteins c-bcl-2 | 2019 |
Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching.
Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prognosis; Propensity Score; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Deoxycytidine; Docetaxel; Drug Resistance; Drug Substitution; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunotherapy; Lung Neoplasms; Neoplasm Staging; Treatment Outcome | 2019 |
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy; Indoles; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2019 |
FOX-A1 contributes to acquisition of chemoresistance in human lung adenocarcinoma via transactivation of SOX5.
Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hepatocyte Nuclear Factor 3-alpha; Humans; Kaplan-Meier Estimate; Male; Mice; Models, Biological; Prognosis; Protein Binding; SOXD Transcription Factors; Transcriptional Activation; Xenograft Model Antitumor Assays | 2019 |
Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Early Detection of Cancer; Humans; Liquid Biopsy; Lung Neoplasms; Male; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2019 |
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Clinical Decision-Making; Consensus; Delphi Technique; Disease Progression; Docetaxel; Humans; Immunotherapy; Indoles; Lung Neoplasms; Mutation; Spain | 2020 |
Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Base Sequence; bcl-X Protein; Caspase 3; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Molecular Sequence Data; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Phenotype; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Signal Transduction; Taxoids; Up-Regulation | 2013 |
Ganetespib AIDS lung cancer survival.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Base Sequence; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 3 Subunit; DNA Methylation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Sequence Data; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Taxoids | 2013 |
HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cytoprotection; Cytosol; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; HMGB1 Protein; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Membrane Proteins; Mice, Inbred NOD; Mice, SCID; Models, Biological; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Protein Transport; Signal Transduction; Taxoids; TOR Serine-Threonine Kinases | 2014 |
Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; MicroRNAs; Proto-Oncogene Mas; Signal Transduction; Taxoids | 2014 |
MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Silencing; Humans; Lung Neoplasms; Male; MicroRNAs; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Taxoids | 2014 |
Bladder and gastric metastases from lung adenocarcinoma harboring codon 13 KRAS mutation: a case report with unusual clinical outcome.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Codon; Cystoscopy; Disease Progression; Docetaxel; Fatal Outcome; Female; Gastroscopy; Humans; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Stomach Neoplasms; Taxoids; Urinary Bladder Neoplasms | 2015 |
Establishment of a highly metastatic model with a newly isolated lung adenocarcinoma cell line.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Proliferation; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplasms, Experimental; Proteomics; Taxoids; Tumor Cells, Cultured | 2015 |
MiR-200b regulates autophagy associated with chemoresistance in human lung adenocarcinoma.
Topics: 3' Untranslated Regions; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Binding Sites; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; MicroRNAs; Middle Aged; RNA Interference; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Taxoids; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2015 |
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Philadelphia; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azepines; Azocines; Benzhydryl Compounds; Camptothecin; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Paclitaxel; Signal Transduction; Taxoids; Time Factors; Topoisomerase Inhibitors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
A double-negative feedback loop between E2F3b and miR- 200b regulates docetaxel chemosensitivity of human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; E2F3 Transcription Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Taxoids; Transfection; Xenograft Model Antitumor Assays | 2016 |
FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gene Knockdown Techniques; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mitochondria; RNA Interference; Taxoids | 2016 |
MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Topics: 3' Untranslated Regions; Adenocarcinoma; Adenocarcinoma of Lung; Antagomirs; Apoptosis; Base Sequence; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Staging; RNA Interference; RNA, Small Interfering; Sequence Alignment; Taxoids | 2017 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Taxoids | 2011 |
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antagonists; Gene Expression; Glutamates; Guanine; Humans; Immunoblotting; Irinotecan; Lung Neoplasms; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Vinblastine; Vinorelbine | 2011 |
MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; E2F3 Transcription Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Middle Aged; Prognosis; Taxoids; Xenograft Model Antitumor Assays | 2012 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2012 |
[Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Docetaxel; Female; Flow Cytometry; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Pemetrexed; T-Lymphocyte Subsets; Taxoids; Young Adult | 2012 |